S

Scribe Therapeutics

SCTXPro tracking

Scribe Therapeutics, Inc. · Nasdaq · CRISPR genetic medicines · Research source · 424B4 · Research as of 2026/07/27 · Latest filing · 10-Q · 2026-11-12 SEC ↗ · SEC checked 2026-11-21

SEC
Saved research available · 424B4

Scribe Therapeutics priced its initial public offering at $15.00 per share and expects to receive approximately $122.8 million in net proceeds from the IPO and concurrent Sanofi private placement.

Research source · 424B4 · Research as of 2026/07/27Latest analyzed filing · 424B4 · 2026-07-27

Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.

SummaryWATCHReport source · 424B4

Newly listed — review valuation, deal quality and post-IPO supply before acting

A clinical-stage biotechnology company developing CRISPR-based genetic medicines. The IPO priced at $15.00 and raised $128.70M.

Full source-backed summary

A clinical-stage biotechnology company developing CRISPR-based genetic medicines. The IPO priced at $15.00 and raised $128.70M. The latest market-value reference is $643.84M; reported revenue is $36.28M and net result is $(35.73M). The offer figures are reconciled to the final prospectus.

Net loss($21,808,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities($45,213,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Voting controlNo controlling party conclusion availableNot separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
Business and development direction

A clinical-stage biotechnology company developing CRISPR-based genetic medicines.

Current business

CRISPR genetic medicines100%

Future development

Future direction not yet disclosed

DECISION DRIVERS

Key risks

High

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

High

Risk 2

The latest reported period remains loss-making.

High

Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

NEXT EVENTFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
LATEST EVIDENCE424B42026/07/27
LISTING CHECKPOINT2026-07-24Nasdaq
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualityThis saved report has no compatible source inputs for this calculation. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1Leerink Partners LLC35.00%3,003,000 shares
2Goldman Sachs & Co. LLC35.00%3,003,000 shares
3Guggenheim Securities, LLC18.00%1,544,400 shares
4Wells Fargo Securities, LLC12.00%1,029,600 shares

Ratio = institution commitment ÷ complete source-table total (8,580,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number of Shares

Number of Shares

SEC table 574 row 8; source 1687975:1691633; SHA256 37b05f0d9afef948756d9a950f4e87b62ffc1138f961cc34324924efde506e83

Leerink Partners LLC: 3003000 / 8580000 × 100

Goldman Sachs & Co. LLC: 3003000 / 8580000 × 100

Guggenheim Securities, LLC: 1544400 / 8580000 × 100

Wells Fargo Securities, LLC: 1029600 / 8580000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.05$ / share
Total underwriting discount$9,009,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

IPO CAPITAL QUALITY

Offering price $ / share$15
Gross offering amount $$128,700,000
Shares offered Shares8,580,000
Issuer proceeds before expenses $$119,691,000
Basis and evidence

No estimate is substituted for missing offer terms.

Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered8,580,000Shares
Offering price$15$ / share
Gross offering amount$128,700,000$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 39 row 1; source 112547:112924; SHA256 0d3c87b3bdd813d2e757245b170bb83b88278a976b25373252c13943778a10ac ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗
IPO investors$128.70Mgross offer size
Issuer / selling holdersSee 424Bprimary-secondary split
Reported revenue$36.28M+86.7%
Net result$(35.73M)latest reported basis
Future supplyLock-upreview holder-specific terms

Proceeds and intended uses

Proceeds and intended uses
MeasureReported valueUnit
Issuer proceeds before expenses$119,691,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Issuer proceeds before expenses

Base prospectus offering; cover per-share and total columns

SEC table 1 row 5; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

Dilution and valuation

IPO price$15Final
Basic post-offer≈ 17.5774M
Equity value≈ $263.6608M
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 17.5774M≈ $263.6608M
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option17,577,386—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option18,864,386—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual2,468,193—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma8,497,386—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted17,577,386—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered8,580,000—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$15
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$128,700,000
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 42 row 1 columns 2; share summary; label column 1; source 114784:115336; SHA256 b6ace2de027f84b77163ddc1050108d979deec67ac06c948000e19bb7e9122c6 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 42 row 1 columns 2; share summary; label column 1; source 114784:115336; SHA256 b6ace2de027f84b77163ddc1050108d979deec67ac06c948000e19bb7e9122c6 ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 313 row 14 columns 1; share summary; label column 1; source 694403:709648; SHA256 0a5d625c10762c97d26590a6aa428ae2759475b16bc8e129acfea766ca2ea877 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 313 row 14 columns 1; share summary; label column 1; source 694403:709648; SHA256 0a5d625c10762c97d26590a6aa428ae2759475b16bc8e129acfea766ca2ea877 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 313 row 14 columns 1; share summary; label column 1; source 694403:709648; SHA256 0a5d625c10762c97d26590a6aa428ae2759475b16bc8e129acfea766ca2ea877 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 39 row 1; source 112547:112924; SHA256 0d3c87b3bdd813d2e757245b170bb83b88278a976b25373252c13943778a10ac ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $15

Exact input · Post-offer shares — base/no option: 17,577,386

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 18,864,386

SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

SEC table 42 row 1 columns 2; share summary; label column 1; source 114784:115336; SHA256 b6ace2de027f84b77163ddc1050108d979deec67ac06c948000e19bb7e9122c6 ↗

SEC valuation primary issuer cover; source 1294:1656; SHA256 b52e9235f8ecd92a5747a7a86c9b5d3c1bd0fd3146a4df4bd4f0259e9101cf03 ↗

SEC valuation summary conditions; source 110539:112476; SHA256 ef3afea562dbcc83595f9765384dec58b64603e409a704a01f2c5f5c57a902bd ↗

SEC valuation summary conditions; source 117255:138549; SHA256 3022a275528db7fbda41c95ad133bd534d621aaa745fc8edf4b3a5f66a783289 ↗

Basis and evidence 9

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

SEC table 42 row 1 columns 2; share summary; label column 1; source 114784:115336; SHA256 b6ace2de027f84b77163ddc1050108d979deec67ac06c948000e19bb7e9122c6 ↗

SEC valuation primary issuer cover; source 1294:1656; SHA256 b52e9235f8ecd92a5747a7a86c9b5d3c1bd0fd3146a4df4bd4f0259e9101cf03 ↗

SEC valuation summary conditions; source 110539:112476; SHA256 ef3afea562dbcc83595f9765384dec58b64603e409a704a01f2c5f5c57a902bd ↗

SEC valuation summary conditions; source 117255:138549; SHA256 3022a275528db7fbda41c95ad133bd534d621aaa745fc8edf4b3a5f66a783289 ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 17,577,386

Exact input · Offering price: $15

SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗

SEC table 42 row 1 columns 2; share summary; label column 1; source 114784:115336; SHA256 b6ace2de027f84b77163ddc1050108d979deec67ac06c948000e19bb7e9122c6 ↗

SEC valuation primary issuer cover; source 1294:1656; SHA256 b52e9235f8ecd92a5747a7a86c9b5d3c1bd0fd3146a4df4bd4f0259e9101cf03 ↗

SEC valuation summary conditions; source 110539:112476; SHA256 ef3afea562dbcc83595f9765384dec58b64603e409a704a01f2c5f5c57a902bd ↗

SEC valuation summary conditions; source 117255:138549; SHA256 3022a275528db7fbda41c95ad133bd534d621aaa745fc8edf4b3a5f66a783289 ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $15 × ≈ 17.5774M shares · Final

Implied equity value≈ $263.6608MPrice × post-offer shares
Post-offer shares≈ 17.5774MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Prior saved context

These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.

IPO price · 8.580M · $128.70M · $15.00

Latest shares outstanding · 18.86M · $643.84M · Market snapshot

Revenue reference · — · $36.28M · +86.7%

Net-result reference · — · $(35.73M) · Loss-making

$15 × 17,577,386 = $263,660,790 [summary-table-42-base-1-price, summary-table-42-base-1-post]

Exact calculation · Derived whole-issuer equity value: $263,660,790

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesComparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗
CONTROLLING PARTYNo controlling party conclusion available

Latest available filing

Economic
~45.5%*
As of
2026/07/27
!Review the beneficial-ownership table and voting rights togetherView source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Scribe Therapeutics
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
Dr. DoudnaOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB; not an additive ownership partitionDisclosedEvidence
our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed—approximately 77.4%Beneficial—
Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately; not an additive ownership partitionDisclosedEvidence
our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed—approximately 38.3%Beneficial—
Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in t; not an additive ownership partitionDisclosedEvidence
entities with which certain of our directors are affiliatedOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partitionDisclosedEvidence
Benjamin L. Oakes, Ph.D.Beneficial shares660,998——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
David L. ParrotBeneficial shares114,860——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Svetlana Lucas, Ph.D.Beneficial shares114,345——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Behzad Aghazadeh, Ph.D.Beneficial shares697,650——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial shares348,825——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
All executive officers and directors as a group (7 persons)Beneficial shares1,936,678——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Entities affiliated with Andreessen HorowitzBeneficial shares2,749,392——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Eli Lilly and CompanyBeneficial shares1,054,828——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Entities affiliated with Avoro Life Sciences Fund LLCBeneficial shares697,650——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Jennifer A. DoudnaBeneficial shares603,547——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Brett T. StaahlBeneficial shares550,056——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Benjamin L. Oakes, Ph.D.Beneficial ownership—7.61%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Benjamin L. Oakes, Ph.D.Beneficial ownership—3.72%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
David L. ParrotBeneficial ownership—1.33%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Svetlana Lucas, Ph.D.Beneficial ownership—1.33%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Behzad Aghazadeh, Ph.D.Beneficial ownership—8.18%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Behzad Aghazadeh, Ph.D.Beneficial ownership—3.96%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—4.09%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—1.98%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
All executive officers and directors as a group (7 persons)Beneficial ownership—21.81%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
All executive officers and directors as a group (7 persons)Beneficial ownership—10.78%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Entities affiliated with Andreessen HorowitzBeneficial ownership—32.24%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Entities affiliated with Andreessen HorowitzBeneficial ownership—15.61%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Eli Lilly and CompanyBeneficial ownership—12.37%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Eli Lilly and CompanyBeneficial ownership—5.99%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Entities affiliated with Avoro Life Sciences Fund LLCBeneficial ownership—8.18%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Entities affiliated with Avoro Life Sciences Fund LLCBeneficial ownership—3.96%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Jennifer A. DoudnaBeneficial ownership—7.08%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Jennifer A. DoudnaBeneficial ownership—3.43%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
Brett T. StaahlBeneficial ownership—6.34%Beneficial—
Percentage of SharesBeneficially Owned; BeforeOfferingDisclosedEvidence
Brett T. StaahlBeneficial ownership—3.1%Beneficial—
Percentage of SharesBeneficially Owned; AfterOfferingDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicableDisclosedEvidence
Source and calculation ↗
Dr. Doudna · Dr. Doudna — Ownership as disclosed · >5%

Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB; not an additive ownership partition

We are party to the UCB Exclusive License Agreement. Dr. Doudna, who holds greater than 5% of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB. See “Business—Material agreements—UCB—Amended and Restated Exclusive License Agreement” for additional information.

0001193125-26-316503 · SEC ownership paragraph; source 1565166:1565741; SHA256 95282cdee4ff72da6b3ae7bb03974f499199f10c998caf5663a8af7f3685d766 ↗

our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates · our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates — Ownership as disclosed · approximately 77.4%

Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately; not an additive ownership partition

Based on the beneficial ownership of our common stock as of July 10, 2026, prior to this offering and the concurrent private placement, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 77.4% of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately 38.3% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group). The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

0001193125-26-316503 · SEC ownership paragraph; source 624663:626113; SHA256 9ed7098bab4dd4a5e2f6321551b6201a27140f7a4ae7b6b6ee313041662f7dd0 ↗

our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates · our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates — Ownership as disclosed · approximately 38.3%

Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in t; not an additive ownership partition

Based on the beneficial ownership of our common stock as of July 10, 2026, prior to this offering and the concurrent private placement, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 77.4% of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately 38.3% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group). The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

0001193125-26-316503 · SEC ownership paragraph; source 624663:626113; SHA256 9ed7098bab4dd4a5e2f6321551b6201a27140f7a4ae7b6b6ee313041662f7dd0 ↗

entities with which certain of our directors are affiliated · entities with which certain of our directors are affiliated — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition

In connection with our Series B Preferred Stock financing, we entered into the IRA with certain holders of our redeemable convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering and the provisions relating to registration rights included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration rights” for additional information.

0001193125-26-316503 · SEC ownership paragraph; source 1565879:1566664; SHA256 c6c108cbd869baa4b3f0082475a6cbf9c571c70d95736c546caf5bc32baf2a8a ↗

Benjamin L. Oakes, Ph.D. · Benjamin L. Oakes, Ph.D. — Beneficial shares · 660,998

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Benjamin L. Oakes, Ph.D.(1)

0001193125-26-316503 · SEC table 535 row 5 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

David L. Parrot · David L. Parrot — Beneficial shares · 114,860

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: David L. Parrot(2)

0001193125-26-316503 · SEC table 535 row 6 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Svetlana Lucas, Ph.D. · Svetlana Lucas, Ph.D. — Beneficial shares · 114,345

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Svetlana Lucas, Ph.D.(3)

0001193125-26-316503 · SEC table 535 row 7 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Behzad Aghazadeh, Ph.D. · Behzad Aghazadeh, Ph.D. — Beneficial shares · 697,650

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Behzad Aghazadeh, Ph.D.(4)

0001193125-26-316503 · SEC table 535 row 9 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial shares · 348,825

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Carl L. Gordon, Ph.D., CFA(5)

0001193125-26-316503 · SEC table 535 row 10 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

All executive officers and directors as a group (7 persons) · All executive officers and directors as a group (7 persons) — Beneficial shares · 1,936,678

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: All executive officers and directors as a group (7 persons)(7)

0001193125-26-316503 · SEC table 535 row 12 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Entities affiliated with Andreessen Horowitz · Entities affiliated with Andreessen Horowitz — Beneficial shares · 2,749,392

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Andreessen Horowitz(8)

0001193125-26-316503 · SEC table 535 row 14 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Eli Lilly and Company · Eli Lilly and Company — Beneficial shares · 1,054,828

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Eli Lilly and Company(9)

0001193125-26-316503 · SEC table 535 row 15 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Entities affiliated with Avoro Life Sciences Fund LLC · Entities affiliated with Avoro Life Sciences Fund LLC — Beneficial shares · 697,650

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)

0001193125-26-316503 · SEC table 535 row 16 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Jennifer A. Doudna · Jennifer A. Doudna — Beneficial shares · 603,547

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Jennifer A. Doudna(10)

0001193125-26-316503 · SEC table 535 row 17 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Brett T. Staahl · Brett T. Staahl — Beneficial shares · 550,056

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Brett T. Staahl(11)

0001193125-26-316503 · SEC table 535 row 18 columns 4; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:3 ↗

Benjamin L. Oakes, Ph.D. · Benjamin L. Oakes, Ph.D. — Beneficial ownership · 7.61%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Benjamin L. Oakes, Ph.D.(1)

0001193125-26-316503 · SEC table 535 row 5 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Benjamin L. Oakes, Ph.D. · Benjamin L. Oakes, Ph.D. — Beneficial ownership · 3.72%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Benjamin L. Oakes, Ph.D.(1)

0001193125-26-316503 · SEC table 535 row 5 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

David L. Parrot · David L. Parrot — Beneficial ownership · 1.33%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: David L. Parrot(2)

0001193125-26-316503 · SEC table 535 row 6 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Svetlana Lucas, Ph.D. · Svetlana Lucas, Ph.D. — Beneficial ownership · 1.33%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Svetlana Lucas, Ph.D.(3)

0001193125-26-316503 · SEC table 535 row 7 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Behzad Aghazadeh, Ph.D. · Behzad Aghazadeh, Ph.D. — Beneficial ownership · 8.18%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Behzad Aghazadeh, Ph.D.(4)

0001193125-26-316503 · SEC table 535 row 9 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Behzad Aghazadeh, Ph.D. · Behzad Aghazadeh, Ph.D. — Beneficial ownership · 3.96%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Behzad Aghazadeh, Ph.D.(4)

0001193125-26-316503 · SEC table 535 row 9 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 4.09%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Carl L. Gordon, Ph.D., CFA(5)

0001193125-26-316503 · SEC table 535 row 10 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 1.98%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Carl L. Gordon, Ph.D., CFA(5)

0001193125-26-316503 · SEC table 535 row 10 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

All executive officers and directors as a group (7 persons) · All executive officers and directors as a group (7 persons) — Beneficial ownership · 21.81%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: All executive officers and directors as a group (7 persons)(7)

0001193125-26-316503 · SEC table 535 row 12 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

All executive officers and directors as a group (7 persons) · All executive officers and directors as a group (7 persons) — Beneficial ownership · 10.78%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: All executive officers and directors as a group (7 persons)(7)

0001193125-26-316503 · SEC table 535 row 12 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Entities affiliated with Andreessen Horowitz · Entities affiliated with Andreessen Horowitz — Beneficial ownership · 32.24%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Entities affiliated with Andreessen Horowitz(8)

0001193125-26-316503 · SEC table 535 row 14 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Entities affiliated with Andreessen Horowitz · Entities affiliated with Andreessen Horowitz — Beneficial ownership · 15.61%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Entities affiliated with Andreessen Horowitz(8)

0001193125-26-316503 · SEC table 535 row 14 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Eli Lilly and Company · Eli Lilly and Company — Beneficial ownership · 12.37%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Eli Lilly and Company(9)

0001193125-26-316503 · SEC table 535 row 15 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Eli Lilly and Company · Eli Lilly and Company — Beneficial ownership · 5.99%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Eli Lilly and Company(9)

0001193125-26-316503 · SEC table 535 row 15 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Entities affiliated with Avoro Life Sciences Fund LLC · Entities affiliated with Avoro Life Sciences Fund LLC — Beneficial ownership · 8.18%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)

0001193125-26-316503 · SEC table 535 row 16 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Entities affiliated with Avoro Life Sciences Fund LLC · Entities affiliated with Avoro Life Sciences Fund LLC — Beneficial ownership · 3.96%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)

0001193125-26-316503 · SEC table 535 row 16 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Jennifer A. Doudna · Jennifer A. Doudna — Beneficial ownership · 7.08%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Jennifer A. Doudna(10)

0001193125-26-316503 · SEC table 535 row 17 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Jennifer A. Doudna · Jennifer A. Doudna — Beneficial ownership · 3.43%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Jennifer A. Doudna(10)

0001193125-26-316503 · SEC table 535 row 17 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

Brett T. Staahl · Brett T. Staahl — Beneficial ownership · 6.34%

Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Brett T. Staahl(11)

0001193125-26-316503 · SEC table 535 row 18 columns 8,9; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:3 ↗

Brett T. Staahl · Brett T. Staahl — Beneficial ownership · 3.1%

Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Brett T. Staahl(11)

0001193125-26-316503 · SEC table 535 row 18 columns 12,13; source 1577833:1590595; SHA256 4657200b97702dc217d7d7dbfd9d575b417e06f05ff65fc1b4abb0e66e4582ec; ownership header cells 2:6,3:6 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our amended and restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our amended and restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt an amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.

0001193125-26-316503 · SEC ownership excerpt; source 1604259:1605088; SHA256 86294d9c8a74b3d35316aed6fbaae2167a2dc3a15d772391810d5dabf4a89873; context source 1600611:1601509; SHA256 9b25583ab1f1dc7dd56ac76c97fd7c4717bdd822d1f430a11072b8e94fac6b8c ↗

Saved control snapshot

The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.

Saved control snapshot
Holder / measureSharesOwnershipVoting rightsReference
Existing holdersMajor ownership group—~54.5%*—
2026/07/27Latest available filing424B4 ↗
Other disclosed classesMajor ownership group—See filing—
2026/07/27Latest available filing424B4 ↗
IPO sharesPublic / new investors—8.580M—
2026/07/27Latest available filing424B4 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

POTENTIAL SUPPLY PRESSURERequires holder-level review

IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.

Initial float
8.580M
Restricted / potential supply
18.86M
Multiple
See filing
Increase
See filing

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
our directors and officers and substantially all of our security holders are, orAfter date of this prospectus · Source conditions apply180 days
We, our executive officers and directors and holders of substantially all of our existing securitiesAfter date of this prospectus · Source conditions apply180 days
Each of our officers, directors and holders of substantially all of our outstanding equity securitiesAfter date of this prospectus · Source conditions apply180 days
Source and calculation
our directors and officers and substantially all of our security holders are, or

All of our directors and officers and substantially all of our security holders are, or will be, subject to lock-up agreements or market standoff provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares of our common stock or options to acquire shares of our common stock or any security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that transfers any of the economic consequences of ownership of our common stock, for a period of 180 days following the date of this prospectus without the prior written consent of Leerink Partners LLC and Goldman Sachs & Co. LLC, subject to certain exceptions. See the section titled “Underwriting” for additional information.

SEC lock-up paragraph; source 1643637:1644636; SHA256 314a0befc98c84429b65c8aa0c706f68bafb9739131e38087b4c278a31dff155 ↗
We, our executive officers and directors and holders of substantially all of our existing securities

We, our executive officers and directors and holders of substantially all of our existing securities have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC and Goldman Sachs & Co. LLC on behalf of the underwriters.

SEC lock-up paragraph; source 1699966:1700493; SHA256 a497b1ef61a825fbfff0e097846262fda841885aeabda2351b528c88d6909ee4 ↗
Each of our officers, directors and holders of substantially all of our outstanding equity securities

Based on the shares outstanding as of March 31, 2026, upon completion of this offering and the concurrent private placement, we will have a total of 17,577,386 shares of common stock outstanding. Of these shares, only the 8,580,000 shares of common stock sold in this offering, or 9,867,000 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and holders of substantially all of our outstanding equity securities have entered into lock-up agreements with the underwriters that restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Leerink Partners LLC and Goldman Sachs & Co. LLC may, in their sole discretion, permit our officers, directors and other current stockholders who are subject to the contractual lock-up to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, the shares of common stock subject to these lock-up agreements will be eligible for sale in the public market, unless held by our officers, directors and their affiliated entities, in which case such shares will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act.

SEC lock-up paragraph; source 618460:620278; SHA256 92726650421e535b833ff2e1cc0d096ea49007a265ab993e2bc5ef3b60d2afcc ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
Over-allotment windowPost-listing See filing · Additional shares only if exercisedOver-allotment window · Additional shares only if exercised
Insider resale eligibilityHolder-specific See 424B · Existing-holder supplyInsider resale eligibility · Existing-holder supply
Basis and evidence
Over-allotment window

Over-allotment window · Additional shares only if exercised

Lock-up / shares eligible for future sale ↗
Insider resale eligibility

Insider resale eligibility · Existing-holder supply

Lock-up / shares eligible for future sale ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported
FY2024($47,786,000)
FY2025($21,808,000)

Operating cash flow

$ · Annual values as reported
FY2024($45,235,000)
FY2025($45,213,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)($47,786,000)($21,808,000)
Operating cash flow($45,235,000)($45,213,000)
Financial quality
CalculationReported value
Cash and cash equivalents2024-12-31$12,602,000
Cash and cash equivalents2025-12-31$12,796,000
Current assets2024-12-31$110,374,000
Current assets2025-12-31$66,934,000
Total assets2024-12-31$127,971,000
Total assets2025-12-31$78,219,000
Current liabilities2024-12-31$35,019,000
Current liabilities2025-12-31$69,057,000
Total liabilities2024-12-31$133,474,000
Total liabilities2025-12-31$101,282,000
Total equity / (deficit)2024-12-31($125,859,000)
Total equity / (deficit)2025-12-31($143,419,000)
General and administrative expensesFY2024$13,163,000
General and administrative expensesFY2025$16,449,000
Cash and cash equivalents2025-12-31 · Unaudited$12,796,000
Cash and cash equivalents2026-03-31 · Unaudited$20,381,000
Current assets2025-12-31 · Unaudited$66,934,000
Current assets2026-03-31 · Unaudited$52,399,000
Total assets2025-12-31 · Unaudited$78,219,000
Total assets2026-03-31 · Unaudited$65,208,000
Current liabilities2025-12-31 · Unaudited$69,057,000
Current liabilities2026-03-31 · Unaudited$79,720,000
Total liabilities2025-12-31 · Unaudited$101,282,000
Total liabilities2026-03-31 · Unaudited$103,590,000
Total equity / (deficit)2025-12-31 · Unaudited($143,419,000)
Total equity / (deficit)2026-03-31 · Unaudited($158,738,000)
General and administrative expenses3M ended 2025-03-31 · Unaudited$6,691,000
General and administrative expenses3M ended 2026-03-31 · Unaudited$3,355,000
Net income / (loss)3M ended 2025-03-31 · Unaudited($3,425,000)
Net income / (loss)3M ended 2026-03-31 · Unaudited($17,347,000)
Operating cash flow3M ended 2025-03-31 · Unaudited($13,621,000)
Operating cash flow3M ended 2026-03-31 · Unaudited($7,555,000)
Basis and evidence
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
General and administrative
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
General and administrative
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
General and administrative
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
General and administrative
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net loss
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net loss
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net cash used in operating activities
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net cash used in operating activities
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Saved snapshot — period not verified

These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.

Financial quality

Financial quality
CalculationReported valueReference
Revenue$36.28M+86.7%
Net result$(35.73M)Latest reported
Market-value reference$643.84MPost-listing snapshot
Shares outstanding18.86MLatest reported
Offer size$128.70M8.580M
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Financial reviewReported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗
Evidence 01Final prospectus source verified

Why it mattersChanges dilution, public float and potential supply.

Evidence · 424B4 · 2026/07/27
Evidence 02Trading began on 2026-07-24 at $15.00

Why it mattersChanges valuation, proceeds and first-day return assumptions.

Evidence · 424B4 · 2026/07/27
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.
2026/07/27
424B4

• Final prospectus source verified

• Trading began on 2026-07-24 at $15.00

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

Potential impact
High
Risk 4

Option exercise, employee equity and lock-up expiry can expand tradable supply.

Potential impact
Medium
Document424B4SEC source document
Filed2026-07-27SEC EDGAR
Research as of2026/07/271 public filings identified
Source-bound table inputs82SEC EDGAR
Open filing ↗
Sources and calculation notes

Final prospectus, offer price, listing date and headline financial evidence reconciled

View the filing's actual first page
Scribe Therapeutics, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR